Related Experiment Video
Updated: Sep 23, 2025
14:38
Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis
Published on: January 4, 2019
18.6K
Platelet-Rich Plasma as an Orthobiologic: Clinically Relevant Considerations
1The Veterinary Sports Medicine and Rehabilitation Center, 4104 Liberty Highway, Anderson, SC 29621, USA.
Summary
Platelet-rich plasma (PRP) is a safe, autologous product concentrated with platelets and growth factors. Different commercial systems produce variable PRP, requiring further research into optimal concentrations for various canine conditions.
Area of Science:
- Veterinary Medicine
- Regenerative Medicine
- Biotechnology
Background:
- Platelet-rich plasma (PRP) is derived from autologous blood, concentrating platelets and growth factors.
- PRP demonstrates good safety and tolerability in humans, equines, and canines.
- Various commercial systems exist for canine PRP preparation.
Purpose of the Study:
- To review the characteristics and variability of PRP products for canine use.
- To highlight the need for further research into optimal PRP component concentrations for specific indications in dogs.
Main Methods:
- Review of existing literature on PRP systems for canine applications.
- Analysis of methodologies used in commercial PRP processing systems.
- Comparison of PRP product variability across different systems.
Main Results:
- Multiple validated commercial systems are available for canine PRP preparation.
- Significant variability exists in PRP products generated by different systems.
- Current understanding of optimal component concentrations for various indications is limited.
Conclusions:
- PRP is a safe and well-tolerated therapeutic option in veterinary medicine.
- The heterogeneity of PRP products across commercial systems necessitates further investigation.
- Optimal component concentrations are crucial for maximizing therapeutic efficacy in canine patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
659
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
659
01:22Formation of the Platelet Plug
7.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.2K